Merck has launched its Parteck COAT excipient — a functional material designed for immediate release film coating applications.
The excipient is a particle engineered polyvinyl alcohol (PVA) with a particle structure that enables rapid dissolution even at low temperatures; this is said to lead to increased process efficiency. The water-soluble particle offers batch-to-batch consistency, contributing to the quality and performance of the final drug product.
The material offers low viscosity in solution, even at high concentrations of 20%, leading to high efficacy. Compared with existing PVAs for coating applications, it has the potential to double the polymer concentration and cut the process time in half.
Other advantages include: a stable moisture barrier to improve stability of moisture-sensitive drug substances; good surface finishing to increase the value of drug formulations; and a high concentration of spraying liquid to increase coating efficacy.
The product is compliant with and surpasses the requirements of all major pharmacopoeias, including United States Pharmacopoeia, European Pharmacopoeia, Chinese Pharmacopoeia and Japanese Pharmaceutical Excipients.
Phone: 1800 800 097
The Native Antigen Company human coronavirus antigens and antibodies
Native Antigen has rapidly expanded its range of SARS-CoV-2 recombinant antigens and antibodies.
TdB Labs dextran sulfate sodium (DSS) for colitis
DSS for colitis is supplied as the sodium salt and is stabilised by a small addition of phosphate...
Merck ReadyStream media preparation system
Merck's Life Science business sector has launched the innovative ReadyStream system — a...
